| Right now, the MarketBeat website is reporting that SXTP has 4 different analyst targets pointing towards an average target of $17.60.
From its closing valuation Friday, that average target suggests well over 300% potential upside. -----
No. 3 SXTP Potential Catalyst - The Company Exercises A Key Agreement Option To Negotiate An Exclusive License.
60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx Use
Company ready to commence regulatory process to secure access to U.S. market for Australian Chestnut Extract as a botanical product for non-prescription uses
WASHINGTON, Jan. 28, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced it has exercised the option in its agreement with Florida State University (FSU) to negotiate an exclusive license to use large-scale purification techniques to extract castanospermine from the seeds of Castanospermum australe (commonly known as the Australian Chestnut, the Moreton Bay Chestnut, and the Black Bean Tree).
Castanospermum australe grows primarily in the Australian states of Queensland and New South Wales, but also in Florida, Hawaii, and California. The processed seeds of Castanospermum australe have historically been a traditional food source in Australia for thousands of years.
According to recent scientific literature, at low doses, castanospermine modulates carbohydrate metabolism, altering glycogen, glucose levels, and other clinical markers. In animal models, high doses have been shown to impact disease outcomes in several therapeutic areas, through immunomodulation.
Castanospermine is also a metabolite of celgosivir, a product that has been evaluated in clinical trials in more than 500 patients against H-I-V and Hepatitis C. Although celgosivir is no longer in commercial development for those indications, that study history suggests castanospermine is safe at achievable doses in humans and is active against the same pharmacological targets as in animal studies.
Since signing its option agreement with FSU in April 2025, the Company has subjected Australian Chestnut Extract to safety testing to ensure compliance with relevant regulatory guidance and has developed and tested various prototype capsule formulations for oral delivery. The Company is now ready to commence a regulatory process to secure access to the U.S. market for Australian Chestnut Extract as a botanical product for non-prescription uses.
Read the full article here. -----
No. 4 SXTP Potential Catalyst - An Important Partnership Is Announced (Adds A Critical Telehealth Platform To Company's ARAKODA® Marketing Strategy.
60 Degrees Pharmaceuticals Announces Partnership with Runway Health to Provide International Travelers Direct Access to ARAKODA® for Malaria Prevention
Partnership adds a travel-focused consumer telehealth platform to the ARAKODA® marketing strategy, offering a new convenience to people planning travel to malaria-endemic regions of the world
ARAKODA is the only FDA-approved, broad spectrum, once-weekly malaria prevention option for international travelers
WASHINGTON, Jan. 22, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced a partnership with Runway Health to expand pre-departure access to ARAKODA® (tafenoquine) for prevention of malaria among international travelers through the Runway Health travel medicine platform.
ARAKODA is the only broad spectrum, once-weekly prescription malaria prevention on the U.S. market.
...
The partnership with Runway Health commences April 2, 2026. It adds a new platform to the 60 Degrees Pharma ARAKODA marketing strategy, where eligible users can match their travel itinerary with a personalized medical treatment plan designed by a U.S. licensed healthcare provider.
Read the full article here. -----
No. 5 SXTP Potential Catalyst - 60 Degrees Pharma Announces Data Supporting Theory That Babesia Infection May Prolong Recovery Times In Patients With Chronic Fatigue.
60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State
Further validates continuation of the B-FREE Study to evaluate the efficacy and safety of ARAKODA® (tafenoquine) for treatment of chronic babesiosis
Data support theory among specialists that Babesia infection may prolong recovery times in patients with chronic fatigue
WASHINGTON, Dec. 29, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that infection with Babesia, a parasite that causes the emerging tick-borne illness called babesiosis, was found in 24 percent of a cohort of 50 patients with chronic fatigue in a study conducted by researchers at North Carolina State University, and published in Pathogens.
Results announced today contribute to efforts to confirm a long-held theory within the U.S. vector-borne disease community that Babesia and chronic disease may be linked – specifically, that Babesia infection may prolong recovery times in patients with chronic fatigue.
The results also reinforce the importance of the B-Free Chronic Babesiosis Study (NCT06656351), which is evaluating efficacy and safety of the ARAKODA regimen of tafenoquine over 90 days for resolution of severe fatigue in patients with chronic babesiosis. The Company’s B-Free Study is now enrolling at the Icahn School of Medicine at Mount Sinai in New York.
“Healthcare providers who treat tick-borne illness may not be surprised by the results of this study,” said 60 Degrees Pharma Chief Executive Officer, Geoffrey Dow. “While the results don’t prove that Babesia infection causes chronic disease, they are consistent with that hypothesis and highlight the need for prospective controlled studies which the Company is now undertaking.”
...
Read the full article here. -----
(Nasdaq: SXTP) Recap - Multiple Potential Catalysts Under Radar Watch
No. 1 - A Tiny Float Could Create A Volatile Situation (In Moments...).
No. 2 - An Average Analyst Target Points To Triple-Digit Potential Upside From Current Chart Levels.
No. 3 - The Company Exercises A Key Agreement Option To Negotiate An Exclusive License.
No. 4 - An Important Partnership Is Announced (Adds A Critical Telehealth Platform To Company's ARAKODA® Marketing Strategy.
No. 5 - 60 Degrees Pharma Announces Data Supporting Theory That Babesia Infection May Prolong Recovery Times In Patients With Chronic Fatigue. -----
We're officially launching coverage on 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP).
Updates will be coming down the pipeline soon. Talk shortly.
Sincerely, FierceAnalyst | Jaks Swift Editorial Writer
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 02/01/2026 and ending on 02/02/2026 to publicly disseminate information about (SXTP:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC seventeen thousand five hundred USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid seventy thousand USD ("Funds"). These Funds were part of the twenty five thousand USD funds that TD Media LLC received from a third party named Momentum Media LLC who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (SXTP:US).
Please see important disclosure information here: https://fierceinvestor.com/disclosure/sxtp-oqgxh/#details | 
0 التعليقات:
إرسال تعليق